Sign in

What researchers published on Amyloidosis

11,961 papers, newest first.

Showing 20 of 242

  • Trial resultUsing dapagliflozin to reduce symptoms in transthyretin cardiac amyloidosis: An n-of-1 trial series pilot study.PloS one
  • Trial resultSafety and tolerability of anselamimab in participants with light chain amyloidosis: Results from a phase 2 study.European journal of cancer (Oxford, England : 1990)
  • Randomised trialEffect of Vutrisiran According to Baseline Tafamidis Use in Transthyretin Amyloidosis With Cardiomyopathy: Insights From HELIOS-B.Journal of the American College of Cardiology
  • Randomised trialInfluence of Disease-Modifying Therapy on the Efficacy of Vutrisiran in Transthyretin Cardiac Amyloidosis.Journal of the American College of Cardiology
  • Randomised trialRight Ventricular Function, Clinical Outcomes, and Effect of Vutrisiran in Transthyretin Amyloidosis With Cardiomyopathy: Secondary Analysis of the HELIOS-B Randomized Clinical Trial.JAMA cardiology
  • Randomised trialLeft Atrial Structure and Function, Clinical Outcomes, and Efficacy of Vutrisiran in Transthyretin Amyloidosis With Cardiomyopathy: A Secondary Analysis of the HELIOS-B Randomized Clinical Trial.JAMA cardiology
  • Trial resultA phase 2 trial of daratumumab monotherapy for patients with newly diagnosed cardiac stage IIIb AL amyloidosis.Blood
  • Trial resultDesign and rationale of the Research with EVuzamitide to Evaluate for cardiac AmyLoidosis (REVEAL) positron emission tomography study: A study of 124I-evuzamitide to diagnose cardiac amyloidosis.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
  • Randomised trialLong-term efficacy and safety of vutrisiran in hereditary transthyretin amyloidosis with polyneuropathy: final analysis of the HELIOS-A randomized treatment extension.Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
  • Randomised trialBaseline characteristics of patients with transthyretin amyloid cardiomyopathy in the CARDIO-TTRansform trial of eplontersen.European journal of heart failure
  • Randomised trialEfficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials.Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • Randomised trialVutrisiran-Mediated Knockdown of Transthyretin in Patients with ATTR Amyloidosis.Clinical pharmacokinetics
  • Randomised trialVutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy and Renal Impairment: Analyses From HELIOS-B.Journal of cardiac failure
  • Randomised trialAcoramidis, Serum Transthyretin, and Cardiovascular Outcomes in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Trial.Journal of cardiac failure
  • Randomised trialDaratumumab-bortezomib-cyclophosphamide-dexamethasone for newly diagnosed amyloidosis: ANDROMEDA final survival analysis.Blood
  • Randomised trialRationale and Design of CARDIO-TTRansform, a Phase 3 Trial of Eplontersen in Transthyretin Amyloid Cardiomyopathy.Circulation. Heart failure
  • Randomised trialEplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy: An Exploratory Analysis of Treatment Effect in Male and Female Patients.Muscle & nerve
  • Trial resultB -Cell Maturation Antigen-CD19 Dual-Targeted Chimeric Antigen Receptor- T -Cell Therapy for Relapsed or Refractory AL Amyloidosis.Journal of the American Society of Nephrology : JASN
  • Randomised trialEffect of Eplontersen in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy Across Genetic Variants: An Exploratory Analysis From the NEURO-TTRansform Trial.European journal of neurology
  • Randomised trialLong-Term Durability of Acoramidis Efficacy in Transthyretin Amyloid Cardiomyopathy: Open-Label Extension of the ATTRibute-CM Randomized Clinical Trial.JAMA cardiology